Trilogy Capital Inc. Has $271,000 Position in Humacyte, Inc. $HUMA

Trilogy Capital Inc. cut its stake in Humacyte, Inc. (NASDAQ:HUMA) by 23.6% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 129,800 shares of the company’s stock after selling 40,000 shares during the period. Trilogy Capital Inc. owned approximately 0.08% of Humacyte worth $271,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of HUMA. Archford Capital Strategies LLC acquired a new stake in shares of Humacyte during the 2nd quarter worth $42,000. Lazari Capital Management Inc. bought a new stake in Humacyte during the second quarter worth about $27,000. Wealth Effects LLC grew its stake in Humacyte by 5.8% during the second quarter. Wealth Effects LLC now owns 102,167 shares of the company’s stock worth $214,000 after buying an additional 5,600 shares in the last quarter. Wealth Enhancement Advisory Services LLC bought a new position in Humacyte in the 2nd quarter valued at about $49,000. Finally, Pallas Capital Advisors LLC bought a new position in Humacyte in the 2nd quarter valued at about $42,000. 44.71% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. HC Wainwright cut their price target on shares of Humacyte from $4.00 to $3.00 and set a “buy” rating for the company in a report on Tuesday, August 12th. TD Cowen cut their target price on Humacyte from $5.00 to $3.50 and set a “buy” rating for the company in a research note on Tuesday, August 12th. Wall Street Zen downgraded Humacyte from a “hold” rating to a “sell” rating in a report on Sunday, August 17th. Barclays started coverage on Humacyte in a report on Wednesday, August 27th. They set an “overweight” rating and a $3.50 price target for the company. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Humacyte in a research note on Tuesday. Six analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, Humacyte presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.29.

Humacyte Price Performance

Shares of HUMA opened at $1.79 on Friday. The company has a quick ratio of 1.93, a current ratio of 2.45 and a debt-to-equity ratio of 2.97. The stock has a market cap of $283.49 million, a PE ratio of -3.98 and a beta of 1.89. Humacyte, Inc. has a 12-month low of $1.15 and a 12-month high of $6.77. The business has a 50-day simple moving average of $1.79 and a two-hundred day simple moving average of $1.99.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.09). The firm had revenue of $0.30 million during the quarter, compared to the consensus estimate of $0.94 million. Analysts anticipate that Humacyte, Inc. will post -1.27 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Humacyte news, CEO Laura E. Niklason sold 591,685 shares of the company’s stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $1.58, for a total value of $934,862.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Brady W. Dougan sold 591,685 shares of Humacyte stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $1.58, for a total transaction of $934,862.30. The disclosure for this sale can be found here. Insiders have sold a total of 4,482,090 shares of company stock worth $7,466,382 over the last three months. Insiders own 5.10% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.